A wealth of evidence has established that cholesterol-lowering statin drugs, widely used for the prevention of cardiovascular disease, do increase the risk of new-onset diabetes, possibly by impairing pancreatic beta cell function and decreasing peripheral insulin sensitivity. Groups at particular risk include the elderly, women, and Asians. The diabetogenic effect of statins appear directly related to statin dose and the degree of attained cholesterol lowering. Statins can cause hyperinsulinemia even in the absence of hyperglycemia and the potential mitogenic effects and implications of prolonged hyperinsulinemia are discussed. Suggestions are made as to how physicians might avert the hyperinsulinemic and diabetogenic effects of statin therapy in clinical practice, and modulate the detrimental effects of these drugs on exercise performance. Finally, long-term studies are needed to determine if the deleterious hyperinsulinemic and diabetogenic effects of statin therapy undermine the beneficial cardiovascular disease risk outcomes in various segments of the population.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Gotto AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012;110(Suppl):3A–14A.
Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J. 1993;295:31–40.
Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with noninsulin dependent diabetes mellitus and hyperlipoproteinemia. Metabolism. 1995;44:212–7.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. For the JUPITER Study Group. N Engl J Med. 2008;359:2195–207.
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71.
Steinberg D. Earlier intervention in the management of hypercholesterolemia: what are we waiting for? J Am Coll Cardiol. 2010;56:627–9.
Pletcher MJ, Hulley SB. Statin therapy in young adults: ready for prime time? J Am Coll Cardiol. 2010;56:637–40.
Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Aging. 2010;39:674–80.
Simons LA, Simons J, Friedlander Y, McCallum J. Predictors of long-term mortality in the elderly: the Dubbo Study. Intern Med J. 2011;41:555–60.
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, et al. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Pressure Institute. Hypertension. 2008;52:30–6.
Goldberg RB, Jacabson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc. 2008;83:470–8.
Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009;53:S28–34.
Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169–81.
Mascitelli L, Goldstein MR. Long-standing statin therapy and the risk of new-onset diabetes in the elderly: collateral damage caused by preventive medicine? Drugs Aging. 2010;29:9–13.
•• Campbell PT, Jacobs EJ, Newton CC, Gapstur SM, Patel AV. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35:1835–44. This very large 26-year observational study shows that diabetes is associated with an increased mortality from a variety of cancers in both men and women.
Barone BB, Yeh H-C, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.
Freeman DJ, Norrie J, Sattar N, Neely DG, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357–62.
Keech A, Hague W, Colquhoun D, Beller E, Best J, Arulchelvam M, et al. For the LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26:2713–21.
Shepherd J, Blauw MB, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. On behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–42.
•• Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77. This post-hoc analysis of the JUPITER trial is notable for the women in the rosuvastatin group exhibiting a significant absolute increase in new-onset diabetes equal to the absolute decrease in the composite primary endpoint of cardiovascular disease events.
Fugh-Berman A. Rosuvastatin in patients with elevated C-reactive protein. N Engl J Med. 2009;360:1038–9.
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:410–4.
Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–40.
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Woman’s Health Initiative. Arch Intern Med. 2012;172:144–52.
Zaharan NL, Williams D, Bennet K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2012. [Epub ahead of print].
Rajpathak SN, Barzilai N, Kumbhani DJ, Alderman M, Crandall J, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924–9.
• Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy; a meta-analysis. JAMA. 2011;305:2556–64. This large meta-analysis shows that intensive compared with moderate-dose statin therapy is associated with a significantly greater risk of new-onset diabetes.
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009;204:483–90.
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycaemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–16.
•• Moutzouri E, Liberopoulos E, Mikhailidis DP, Kostapanos MS, Kei AA, Milionis H, et al. Comparison of the effects of simvastatin vs rosuvastatin vs simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011;65:1141–8. This study demonstrates that statin therapy can significantly increase fasting insulin levels without having an effect on fasting glucose or glycosylated hemoglobin levels.
Koh KK, Ahn JY, Quon MJ, Kim SJ, Han SH, Koh Y, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31:776–82.
Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51:701–13.
Defronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32:S157–63.
Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic β-cells. Endocrinology. 2008;149:5136–45.
• Brown JE. The ageing pancreas. Br J Diabetes Vasc Dis. 2012;12:141–5. This interesting paper notes that the aging pancreas is associated with impaired beta cell function, implies that the elderly might be particularly sensitive to statin induced beta cell dysfunction.
•• Kwak H-B, Thalacker-Mercer A, Anderson EJ, Lin C-T, Kane DA, Lee N-S, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med. 2012;52:198–207. This paper shows how simvastatin results in skeletal muscle mitochondrial dysfunction.
Galtier F, Mura T, de Mauverger ER, Chevassus H, Farret A, Gagnol J-P, et al. Effect of high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol. 2012;263:281–6.
• Hoeks J, Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab. 2012;23:444–50. This interesting paper connects skeletal muscle mitochondrial dysfunction with insulin resistance.
Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab. 2012;23:435–43.
• Supale S, Li N, Brun T, Maechler P. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab. 2012;23:477–87. This paper suggests pancreatic beta cell mitochondrial dysfunction leads to beta cell apoptosis and cell death.
Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001;507:357–61.
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia. 2006;49:1881–92.
Shepherd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–57.
Chidlow Jr JH, Sessa WC. Caveolae, caveolins, and cavins; complex control of cellular signaling and inflammation. Cardiovasc Res. 2010;86:219–25.
Breen MR, Camps M, Carvalho-Simoes F, Zorzano A, Pilch PF. Cholesterol depletion in adipocytes causes caveolae collapse concomitant with proteosomal degradation of cavin-2 in a switch-like fashion. PLoS One. 2012;7:e34516.
González-Muñoz E, López-Iglesias C, Calvo M, Palacin M, Zorzano A, Camps M. Caveolin-1 loss of function accelerates glucose transporter 4 and insulin receptor degradation in 3T3-L1 adipocytes. Endocrinology. 2009;150:3493–502.
Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–33.
• Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis. 2012. [Epub ahead of print]. This important study shows that muscular side effects from average doses of statins in real-life clinical situations are much more common than what has been seen in clinical trials.
Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393–403.
Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210:94–102.
Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180–2.
Scott D, Blizzard L, Fell J, Jones G. The epidemiology of sarcopenia in community living older adults: what role does lifestyle play? J Cachex Sarcopenia Muscle. 2011;2:125–34.
Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: pathogenesis and consequences. Br J Diabetes Vasc Dis. 2011;11:230–4.
•• Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al, for the DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia. 2010;53:1867–76. This large observational study shows that pre-diabetes and diabetes are risk factors for cancer mortality in men and women irrespective of body mass index.
Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: a meta-analysis of epidemiological evidence in Asians and non-Asians. J Diabetes Invest. 2012;3:24–33.
Tsugane S, Inoue M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 2010;101:1073–9.
Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia. 2010;53:2086–8.
Cowie CC, Williams DE, Rust KF, Gregg EW, Ford ES, Bainbridge KE, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005–2006. Diabetes Care. 2009;32:287–94.
Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012;62:118–28.
DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.
Gallagher EJ, LeRoith D. Mini-review: IGF, insulin, and cancer. Endocrinology. 2011;152:2546–51.
• Pollak M. The insulin and insulin-like growth factor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–69. This is a great review on the mechanisms of hyperinsulinemia and insulin growth factor signaling in oncogenesis.
Giovannucci E, Habel LA, Harlan DM, Pollak M, Archer MC, Regensteiner JG, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.
Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes. 2010;1:116–28.
Jardé T, Perrier S, Vasson M-P, Caldefie-Chézet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 2011;47:33–43.
Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–5.
Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol. 2011;29:32–9.
Goldstein MR, Mascitelli L. Statin-induced diabetes: perhaps, it’s the tip of the iceberg. Q J Med. 2011;104:174–8.
Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS. 2008;116:615–28.
• Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012;6:303–9. This paper challenges the dogma that achieving ultra-low cholesterol levels with maximal doses of statins yields significantly better clinical results.
Ferenczi EA, Asaria P, Hughes AD, Chaturvedi N, Francis DP. Can a statin neutralize the cardiovascular risk of unhealthy dietary choices? Am J Cardiol. 2010;106:587–92.
Mizuno K, Tajima Y, Ohashi Y, Nakamura H. Is the risk of new-onset diabetes by statins associated with diet adherence? Int J Cardiol. 2012. [Epub ahead of print].
Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, for the Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243–51.
Jula A, Marniemi J, Huupponen R, Virtanen A, Rastas M, Rönnemaa T. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002;287:598–605.
Caprio S. Calories from soft drinks—do they matter? N Engl J Med. 2012;367:1462–3.
Qi Q, Chu AY, Kang JH, Jensen MK, Curhan GC, Pasquale LR, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med. 2012;367:1387–96.
Tappy L, Lê K-A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90:23–46.
Port AM, Ruth MR, Istfan NW. Fructose comsumption and cancer: is there a connection? Curr Opin Endocrinol Diabetes Obes. 2012;19:367–74.
Pomeranz JL, Brownell KB. Portion sizes and beyond—Government’s legal authority to regulate food industry practices. N Engl J Med. 2012;367:1383–5.
Roden M. Exercise in type 2 diabetes: to resist or to endure? Diabetologia. 2012;55:1235–9.
Lira VA, Benton CR, Yan Z, Bonen A. PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab. 2010;299:E145–61.
• Grontved A, Rimm EB, Willett WC, Anderson LB, Hu FB. A prospective study of weight training and risk of type 2 diabetes mellitus in men. Arch Intern Med. 2012;172:1306–12. This paper suggests that combined resistance and endurance exercise provide the best results in decreasing the risk of diabetes.
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40:188–94.
Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10:16–21.
Binkley N, Ramamurthy R, Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin N Am. 2010;39:287–301.
Borges MC, Martini LA, Rogero MM. Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition. 2011;27:399–404.
Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351385.
Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25(OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009;153:11–6.
Booth FW, Hargreaves M. Understanding multi-organ pathology from insufficient exercise. J Appl Physiol. 2011;111:1199–200.
Thyfault JP, Krogh-Madsen R. Metabolic disruptions induced by reduced ambulatory activity in free-living humans. J Appl Physiol. 2011;111:1218–24.
Conflict of Interest
Mark R. Goldstein declares that he has no conflict of interest.
Luca Mascitelli declares that he has no conflict of interest.
About this article
Cite this article
Goldstein, M.R., Mascitelli, L. Do Statins Cause Diabetes?. Curr Diab Rep 13, 381–390 (2013). https://doi.org/10.1007/s11892-013-0368-x
- Insulin resistance
- Mitochondrial dysfunction